Prednisone to protect the liver during focused radiation for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether prednisone (an anti-inflammatory steroid) can help protect the liver in people with hepatocellular carcinoma who are getting stereotactic body radiation therapy. It may reduce liver stress from radiation and help you tolerate treatment safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer called hepatocellular carcinoma, confirmed by biopsy or by specific scan findings
- You’ve had any prior liver procedures (like radiation, RFA, or TACE) at least 4 weeks ago, and you’re fully recovered
- Your overall health is good enough for treatment (performance status 0 to 2)
- You are age 18 or older and can sign the study consent form
- You have signs you’re higher risk for liver strain (for example, certain lab/score results, or larger treated tumor size)
- You can safely take steroids like prednisone (no steroid allergy, no serious uncontrolled infections, and blood sugar is under control)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a standard radiation dose plan versus a plan that adjusts the dose based on how the tumor responds to radiation-related measurements. It aims to improve how well stereotactic body radiation therapy (SBRT) treats liver cancer while keeping side effects manageable.
This trial is testing whether giving focused radiation therapy (SBRT) after liver surgery helps lower the chance of cancer coming back. It is for people whose surgery left a very small safety margin around the tumor.
This trial tests a combination of liver-directed radiation therapy, an immunotherapy drug (which helps your immune system fight cancer), and a drug that blocks blood vessel growth to the tumor. It is for people with advanced liver cancer that cannot be treated with surgery.
This study tests whether a precise type of radiation (called stereotactic body radiotherapy or SBRT) can be used as a 'bridge' to keep your liver cancer from growing while you wait for a liver transplant. It may help more people stay healthy enough to receive a transplant.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.